World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
By: Liliana Laranjo, Fernando Lanas, Marie Chan Sun, Deborah Anne Chen, Lisa Hynes, Tasnim F. Imran, Dhruv S. Kazi, Andre Pascal Kengne, Maki Komiyama, Masanari Kuwabara, Jeremy Lim, Pablo Perel, Daniel José Piñeiro, Carlos I. Ponte-Negretti, Tania Séverin, David R. Thompson, Lale Tokgözoğlu, Lijing L. Yan and Clara K. Chow
References
- Perel P, Avezum A, Huffman M, et al. Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Glob Heart. 2015; 10(2): 99–110. DOI: 10.1016/j.gheart.2015.04.003
- Grainger Gasser A, Welch C, Arora M, et al. Reducing Cardiovascular Mortality Through Tobacco Control: A World Heart Federation Roadmap. Glob Heart. 2015; 10(2): 123–133. DOI: 10.1016/j.gheart.2015.04.007
- Jeemon P, Séverin T, Amodeo C, et al. World Heart Federation Roadmap for Hypertension—A 2021 Update. Glob Heart. 2021; 16(1): 63. DOI: 10.5334/gh.1066
- Ray KK, Ference BA, Séverin T, et al. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022; 17(1): 75. DOI: 10.5334/gh.1154
- Freedman B, Hindricks G, Banerjee A, et al. World Heart Federation Roadmap on Atrial Fibrillation—A 2020 Update. Glob Heart. 2021; 16(1): 41. DOI: 10.5334/gh.1023
- Palafox B, Mocumbi AO, Kumar RK, et al. The WHF Roadmap for Reducing CV Morbidity and Mortality Through Prevention and Control of RHD. Glob Heart. 2017; 12(1): 47–62. DOI: 10.1016/j.gheart.2016.12.001
- Mitchell S, Malanda B, Damasceno A, et al. A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. Glob Heart. 2019; 14(3): 215–240. DOI: 10.1016/j.gheart.2019.07.009
- Ferreira JP, Kraus S, Mitchell S, et al. World Heart Federation Roadmap for Heart Failure. Glob Heart. 2019; 14(3): 197–214. DOI: 10.1016/j.gheart.2019.07.004
- Echeverría LE, Marcus R, Novick G, et al. WHF IASC Roadmap on Chagas Disease. Glob Heart. 2020; 15(1): 26. DOI: 10.5334/gh.484
- Tromp J, Jindal D, Redfern J, et al. World Heart Federation Roadmap for Digital Health in Cardiology. Glob Heart. 2022; 17(1): 61. DOI: 10.5334/gh.1141
- The World Heart Federation, Severin T, Champagne B, et al. World Heart Vision 2030: Driving Policy Change. Geneva, Switzerland; 2022.
- World Heart Federation. World Heart Report 2023: Confronting the World’s Number One Killer. Geneva, Switzerland; 2023.
- Lindstrom M, DeCleene N, Dorsey H, et al. Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990–2021. J Am Coll Cardiol. 2022; 80(25): 2372–2425. DOI: 10.1016/j.jacc.2022.11.001
- World Health Organization. Cardiovascular diseases (CVDs); Key facts.
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) . Published 2021. Accessed January 10, 2023. - Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25): 2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Mendis S, Puska P, Norrving B, World Health Organization, World Heart Federation, et al. Global Atlas on Cardiovascular Disease Prevention and Control; 2011.
- Goff DC,
Jr. , Khan SS, Lloyd-Jones D, et al. Bending the Curve in Cardiovascular Disease Mortality: Bethesda + 40 and Beyond. Circulation. 2021; 143(8): 837–851. DOI: 10.1161/CIRCULATIONAHA.120.046501 - Ponte-Negretti CI, Wyss FS, Piskorz D, et al. Considerations and Guidance for the Structure, Organisation, and Operation of Cardiometabolic Prevention Units: A Consensus Statement of the Inter-American Society of Cardiology. Glob Heart. 2021; 16(1): 27. DOI: 10.5334/gh.960
- Blumenthal JA, Sherwood A, Smith PJ, et al. Enhancing Cardiac Rehabilitation with Stress Management Training: A Randomized, Clinical Efficacy Trial. Circulation. 2016; 133(14): 1341–1350. DOI: 10.1161/CIRCULATIONAHA.115.018926
- Mendis S, Graham I, Narula J. Addressing the Global Burden of Cardiovascular Diseases: Need for Scalable and Sustainable Frameworks. Glob Heart. 2022; 17(1):
48 . DOI: 10.5334/gh.1139 - Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Developed by the Task Force for Cardiovascular Disease Prevention in Clinical Practice with Representatives of the European Society Of Cardiology and 12 Medical Societies with the Special Contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal. 2021; 42: 3227–3337. DOI: 10.1093/eurheartj/ehab484
- World Health Organization.
Web Annex A. World Health Organization Model List of Essential Medicines – 23rd List, 2023 . In: The selection and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24 – 28 April 2023. Geneva: World Health Organization; 2023. - Aktaa S, Gencer B, Arbelo E, et al. European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: Developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in Collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2022; 29(7): 1060–1071. DOI: 10.1093/eurjpc/zwab160
- Bays HE, Kulkarni A, German C, et al. Ten Things to Know About Ten Cardiovascular Disease Risk Factors – 2022. Am J Prev Cardiol. 2022; 10:
100342 . DOI: 10.1016/j.ajpc.2022.100342 - Webster R, Murphy A, Bygrave H, Ansbro É, Grobbee DE, Perel P. Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases. Glob Heart. 2020; 15(1). DOI: 10.5334/gh.860
- Centers for Disease Control and Prevention. Best Practices for Heart Disease and Stroke – A Guide to Effective Approaches and Strategies. Centers for Disease Control and Prevention; 2022.
- Schwalm J-D, McKee M, Huffman MD, Yusuf S. Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation. 2016; 133(8): 742–755. DOI: 10.1161/CIRCULATIONAHA.115.008721
- Singh K, Bawa VS, Venkateshmurthy NS, et al. Assessment of Studies of Quality Improvement Strategies to Enhance Outcomes in Patients with Cardiovascular Disease. JAMA Network Open. 2021; 4(6):
e2113375 –e2113375. DOI: 10.1001/jamanetworkopen.2021.13375 - Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148(9): e9–e119. DOI: 10.1161/CIR.0000000000001183
- Fox KA, Metra M, Morais J, Atar D. The Myth of ‘Stable’ Coronary Artery Disease. Nature Reviews Cardiology. 2020; 17(1): 9–21. DOI: 10.1038/s41569-019-0233-y
- Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-Pathway Inhibition for Secondary and Tertiary Antithrombotic Prevention in Cardiovascular Disease. Nature Reviews Cardiology. 2020; 17(4): 242–257. DOI: 10.1038/s41569-019-0314-y
- Kerr AJ, Broad J, Wells S, Riddell T, Jackson R. Should the First Priority in Cardiovascular Risk Management Be Those with Prior Cardiovascular Disease? Heart. 2009; 95(2): 125–129. DOI: 10.1136/hrt.2007.140905
- Yusuf S. Two Decades of Progress in Preventing Vascular Disease. Lancet (London, England). 2002; 360(9326): 2–3. DOI: 10.1016/S0140-6736(02)09358-3
- Taylor RS, Dalal HM, McDonagh ST. The Role of Cardiac Rehabilitation in Improving Cardiovascular Outcomes. Nature Reviews Cardiology. 2022; 19(3): 180–194. DOI: 10.1038/s41569-021-00611-7
- Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022; 80(14): 1366–1418. DOI: 10.1016/j.jacc.2022.07.006
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319–1330. DOI: 10.1056/NEJMoa1709118
- Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012; 366(1): 9–19. DOI: 10.1056/NEJMoa1112277
- Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 Inhibitors and GLP-1 Receptor Agonists: Established and Emerging Indications. Lancet. 2021; 398(10296): 262–276. DOI: 10.1016/S0140-6736(21)00536-5
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023; 388(15): 1353–1364. DOI: 10.1056/NEJMoa2215024
- Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61(4): 404–410. DOI: 10.1016/j.jacc.2012.10.027
- Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in Cardiovascular Disease: In-Depth Review. Circulation. 2022; 145(1): 61–78. DOI: 10.1161/CIRCULATIONAHA.121.056171
- Ortega-Paz L, Capodanno D, Angiolillo DJ. Canakinumab for Secondary Prevention of Coronary Artery Disease. Future Cardiology. 2021; 17(3): 427–442. DOI: 10.2217/fca-2020-0211
- Tardif J-C, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England J Med. 2019; 381(26): 2497–2505. DOI: 10.1056/NEJMoa1912388
- Nidorf SM, Fiolet AT, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. New England J Med. 2020; 383(19): 1838–1847. DOI: 10.1056/NEJMoa2021372
- Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England J Med. 2019; 380(8): 752–762. DOI: 10.1056/NEJMoa1809798
- Jaiswal V, Ang SP, Yaqoob S, et al. Cardioprotective Effects of Influenza Vaccination among Patients with Established Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis. Eur J Prev Cardiol. 2022; 29(14): 1881–1892. DOI: 10.1093/eurjpc/zwac152
- Diaz-Arocutipa C, Saucedo-Chinchay J, Mamas MA, Vicent L. Influenza Vaccine Improves Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis. Travel Medicine and Infectious Disease; 2022:
102311 . DOI: 10.1016/j.tmaid.2022.102311 - Maniar YM, Al-Abdouh A, Michos ED. Influenza Vaccination for Cardiovascular Prevention: Further Insights from the IAMI Trial and an Updated Meta-Analysis. Current Cardiology Reports. 2022; 24(10): 1327–1335. DOI: 10.1056/NEJMoa1702090
- Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018; 378(4): 345–353. DOI: 10.1056/NEJMoa1702090
- Driggin E, Maddox TM, Ferdinand KC, et al. ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77(15): 1938–1948. DOI: 10.1016/j.jacc.2021.02.017
- Eurich DT, Johnstone JJ, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Pneumococcal Vaccination and Risk Of Acute Coronary Syndromes in Patients with Pneumonia: Population-Based Cohort Study. Heart. 2012; 98(14): 1072–1077. DOI: 10.1136/heartjnl-2012-301743
- McEvoy JW, Jennings C, Kotseva K, et al. INTERASPIRE: An International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions: In Partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology. Curr Cardiol Rep. 2021; 23(10): 136. DOI: 10.1007/s11886-021-01568-2
- Teo K, Lear S, Islam S, et al. Prevalence of a Healthy Lifestyle among Individuals with Cardiovascular Disease in High-, Middle- and Low-Income Countries: The Prospective Urban Rural Epidemiology (PURE) study. Jama. 2013; 309(15): 1613–1621. DOI: 10.1001/jama.2013.3519
- Yusuf S, Islam S, Chow CK, et al. Use of Secondary Prevention Drugs for Cardiovascular Disease in the Community in High-Income, Middle-Income, and Low-Income Countries (the PURE Study): A Prospective Epidemiological Survey. The Lancet. 2011; 378(9798): 1231–1243. DOI: 10.1016/S0140-6736(11)61215-4
- Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and Impact on Cardiovascular Risk Factor Control in Coronary Patients across 27 Countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V Registry. Eur J Prev Cardiol. 2019; 26(8): 824–835. DOI: 10.1177/2047487318825350
- Pedretti RFE, Hansen D, Ambrosetti M, et al. How to Optimize the Adherence to a Guideline-Directed Medical Therapy in the Secondary Prevention of Cardiovascular Diseases: A Clinical Consensus Statement from the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol; 2022. DOI: 10.1093/eurjpc/zwac204
- De Bacquer D, Astin F, Kotseva K, et al. Poor Adherence to Lifestyle Recommendations in Patients with Coronary Heart Disease: Results from the EUROASPIRE Surveys. European Journal of Preventive Cardiology. 2022; 29(2): 383–395. DOI: 10.1093/eurjpc/zwab115
- Yue J, Kazi S, Nguyen T, Chow CK. Comparing Secondary Prevention for Patients with Coronary Heart Disease and Stroke Attending Australian General Practices: A Cross-Sectional Study Using Nationwide Electronic Database. BMJ Qual Saf; 2023. DOI: 10.1136/bmjqs-2022-015699
- Lu J, Zhang L, Lu Y, et al. Secondary Prevention of Cardiovascular Disease in China. Heart. 2020; 106(17): 1349–1356. DOI: 10.1136/heartjnl-2019-315884
- Yoo SGK, Chung GS, Bahendeka SK, et al. Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries. Jama. 2023; 330(8): 715–724. DOI: 10.1001/jama.2023.12905
- Walli-Attaei M, Joseph P, Rosengren A, et al. Variations between Women and Men in Risk Factors, Treatments, Cardiovascular Disease Incidence, and Death in 27 High-Income, Middle-Income, and Low-Income Countries (PURE): A Prospective Cohort Study. Lancet. 2020; 396(10244): 97–109. DOI: 10.1016/S0140-6736(20)30543-2
- Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries. N Eng J Med. 2014; 371(9): 818–827. DOI: 10.1056/NEJMoa1311890
- Mendis S, Abegunde D, Yusuf S, et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ. 2005; 83(11): 820–829.
- Marcus ME, Manne-Goehler J, Theilmann M, et al. Use of Statins for the Prevention of Cardiovascular Disease in 41 Low-Income and Middle-Income Countries: A Cross-Sectional Study of Nationally Representative, Individual-Level Data. Lancet Glob Health. 2022; 10(3): e369–e379. DOI: 10.1016/S2214-109X(21)00551-9
- Schutte AE, Jafar TH, Poulter NR, et al. Addressing Global Disparities in Blood Pressure Control: Perspectives of the International Society of Hypertension. Cardiovascular Research. 2023; 119(2): 381–409. DOI: 10.1093/cvr/cvac130
- Nogueira L, White KE, Bell B, et al. The Role of Behavioral Medicine in Addressing Climate Change-Related Health Inequities. Transl Behav Med. 2022; 12(4): 526–534. DOI: 10.1093/tbm/ibac005
- Jacobsen AP, Khiew YC, Duffy E, et al. Climate Change and the Prevention of Cardiovascular Disease. Am J Prev Cardiol. 2022; 12:
100391 . DOI: 10.1016/j.ajpc.2022.100391 - Collaboration AT. Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients. Bmj. 2002; 324(7329): 71–86. DOI: 10.1136/bmj.324.7329.71
- Galper BZ, Mauri L. Antiplatelet Therapy after Coronary Stenting. Current Treatment Options in Cardiovascular Medicine. 2013; 15: 1–10. DOI: 10.1007/s11936-012-0223-4
- Kinlay S, Young MM, Sherrod R, Gagnon DR. Long-Term Outcomes and Duration of Dual Antiplatelet Therapy after Coronary Intervention with Second-Generation Drug-Eluting Stents: The Veterans Affairs Extended DAPT Study. Journal of the American Heart Association. 2023; 12(2):
e027055 . DOI: 10.1161/JAHA.122.027055 - Kedhi E, Delewi R, Fabris E, et al. Duration of Dual Antiplatelet Therapy after Myocardial Infarction: Insights from a Pooled Database of the SMART-DATE and DAPT-STEMI Trials. Atherosclerosis. 2020; 315: 55–61. DOI: 10.1016/j.atherosclerosis.2020.11.003
- Group HPSC. MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20 536 High-Risk Individuals: A Randomised Placebocontrolled Trial. The Lancet. 2002; 360(9326): 7–22. DOI: 10.1016/S0140-6736(02)09327-3
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur Heart J. 2020; 41(1): 111–188. DOI: 10.1093/eurheartj/ehz455
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73(24): 3168–3209. DOI: 10.1016/j.jacc.2018.11.002
- Baigent C, Keech A, Kearney PM, et al. Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins. Lancet. 2005; 366(9493): 1267–1278. DOI: 10.1016/S0140-6736(05)67394-1
- Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after Myocardial Infarction: Systematic Review and Meta Regression Analysis. Bmj. 1999; 318(7200): 1730–1737. DOI: 10.1136/bmj.318.7200.1730
- Andersson C, Shilane D, Go AS, et al. Beta-Blocker Therapy And Cardiac Events among Patients with Newly Diagnosed Coronary Heart Disease. Journal of the American College of Cardiology. 2014; 64(3): 247–252. DOI: 10.1016/j.jacc.2014.04.042
- Yusuf S, Sleight P, Pogue Jf, Bosch J, Davies R, Dagenais G. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Eng J Med. 2000; 342(3): 145–153. DOI: 10.1056/NEJM200001203420301
- Lewis CE, Fine LJ, Beddhu S, et al. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021; 384(20): 1921–1930. DOI: 10.1056/NEJMoa1901281
- NDA approval (215727) June 2023. US Food and Drug Administration.
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215727Orig1s000ltr.pdf . Published 2023. Accessed. - Behrouzi B, Bhatt DL, Cannon CP, et al. Association of Influenza Vaccination with Cardiovascular Risk: A Meta-analysis. JAMA Netw Open. 2022; 5(4):
e228873 . DOI: 10.1001/jamanetworkopen.2022.8873 - Fröbert O, Götberg M, Erlinge D, et al. Influenza Vaccination after Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021; 144(18): 1476–1484. DOI: 10.1161/CIRCULATIONAHA.121.057042
- Barbetta L, Correia ETO, Gismondi R, Mesquita ET. Influenza Vaccination as Prevention Therapy for Stable Coronary Artery Disease and Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials. Am J Med. 2023; 136(5): 466–475. DOI: 10.1016/j.amjmed.2023.02.004
- Dibben GO, Faulkner J, Oldridge N, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: A Meta-Analysis. Eur Heart J. 2023; 44(6): 452–469. DOI: 10.1093/eurheartj/ehac747
- Shields GE, Wells A, Doherty P, Heagerty A, Buck D, Davies LM. Cost-Effectiveness of Cardiac Rehabilitation: A Systematic Review. Heart. 2018; 104(17): 1403–1410. DOI: 10.1136/heartjnl-2017-312809
- Ambrosetti M, Abreu A, Corrà U, et al. Secondary Prevention through Comprehensive Cardiovascular Rehabilitation: From Knowledge to Implementation. 2020 Update. A Position Paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol; 2020. DOI: 10.1177/2047487320913379
- Hansen D, Abreu A, Ambrosetti M, et al. Exercise Intensity Assessment and Prescription in Cardiovascular Rehabilitation and Beyond: Why and How: A Position Statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022; 29(1): 230–245. DOI: 10.1093/eurjpc/zwab007
- Eijsvogels TM, Maessen MF, Bakker EA, et al. Association of Cardiac Rehabilitation with All-Cause Mortality among Patients with Cardiovascular Disease in the Netherlands. JAMA Network Open. 2020; 3(7) :
e2011686 –e2011686. DOI: 10.1001/jamanetworkopen.2020.11686 - Beatty AL, Beckie TM, Dodson J, et al. A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities. Circulation. 2023; 147(3): 254–266. DOI: 10.1161/CIRCULATIONAHA.122.061046
- Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking Cessation for Secondary Prevention of Cardiovascular Disease. Cochrane Database of Systematic Reviews. 2022; 8. DOI: 10.1002/14651858.CD014936.pub2
- Robijn AL, Woodward M, Pearson SA, et al. Uptake of Prescription Smoking Cessation Pharmacotherapies after Hospitalization for Major Cardiovascular Disease. Eur J Prev Cardiol. 2022; 29(17): 2173–2182. DOI: 10.1093/eurjpc/zwac172
- Krist AH, Davidson KW, Mangione CM, et al. Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement. Jama. 2021; 325(3): 265–279. DOI: 10.1001/jama.2020.25019
- E-cigarettes are Harmful to Health. WHO.
https://www.who.int/news/item/05-02-2020-e-cigarettes-are-harmful-to-health . Published 2020. Accessed. - Kennedy CD, van Schalkwyk MCI, McKee M, Pisinger C. The Cardiovascular Effects of Electronic Cigarettes: A Systematic Review of Experimental Studies. Prev Med. 2019; 127:
105770 . DOI: 10.1016/j.ypmed.2019.105770 - Bianco E, Skipalskyi A, Goma F, et al. E-Cigarettes: A New Threat to Cardiovascular Health – A World Heart Federation Policy Brief. Glob Heart. 2021; 16(1): 72. DOI: 10.1177/2047487320941993
- Kavousi M, Pisinger C, Barthelemy JC, et al. Electronic Cigarettes and Health with Special Focus on Cardiovascular Effects: Position Paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2020; 2047487320941993. DOI: 10.1177/2047487320941993
- World Health Organization. Physical Activity: Key Facts.
https://www.who.int/news-room/fact-sheets/detail/physical-activity . Published 2022. Accessed 10 January, 2023. - Karam G, Agarwal A, Sadeghirad B, et al. Comparison of Seven Popular Structured Dietary Programmes and Risk of Mortality and Major Cardiovascular Events in Patients at Increased Cardiovascular Risk: Systematic Review and Network Meta-Analysis. Bmj. 2023; 380. DOI: 10.1136/bmj-2022-072003
- Anderson BO, Berdzuli N, Ilbawi A, et al. Health and Cancer Risks Associated with Low Levels of Alcohol Consumption. The Lancet Public Health. 2023; 8(1): e6–e7. DOI: 10.1016/S2468-2667(22)00317-6
- Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-Term Secondary Prevention of Cardiovascular Disease with a Mediterranean Diet and a Low-Fat Diet (CORDIOPREV): A Randomised Controlled Trial. Lancet. 2022; 399(10338): 1876–1885. DOI: 10.1016/S0140-6736(22)00122-2
- Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and Cardiovascular Disease: Mechanistic Insights and Management Strategies. A Joint Position Paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022; 29(17): 2218–2237. DOI: 10.1093/eurjpc/zwac187
- Aminian A, Zajichek A, Arterburn DE, et al. Association of Metabolic Surgery with Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes and Obesity. Jama. 2019; 322(13): 1271–1282. DOI: 10.1001/jama.2019.14231
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Nov 11. DOI: 10.1056/NEJMoa230756
- Miller V, Nambiar L, Saxena M, et al. Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings from a Multistakeholder, Qualitative Analysis. Global Heart. 2018; 13(1): 27–34. e17. DOI: 10.1016/j.gheart.2017.08.001
- Banerjee A, Khandelwal S, Nambiar L, et al. Health System Barriers and Facilitators to Medication Adherence for the Secondary Prevention of Cardiovascular Disease: A Systematic Review. Open Heart. 2016; 3(2):
e000438 . DOI: 10.1136/openhrt-2016-000438 - Lamelas PM, Yusuf S, Schwalm J. Effective Approaches to Address the Global Cardiovascular Disease Burden. Current Opinion in Cardiology. 2017; 32(5): 557–566. DOI: 10.1097/HCO.0000000000000433
- Uchmanowicz I, Hoes A, Perk J, et al. Optimising Implementation of European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: What Is Needed? Eur J Prev Cardiol. 2021; 28(4): 426–431. DOI: 10.1177/2047487320926776
- Schwalm J, Walli-Attaei M, Yusuf S. New Approaches Needed to Improve Prevention of Cardiovascular Disease. JAMA Network Open. 2023; 6(1):
e2251162 –e2251162. DOI: 10.1001/jamanetworkopen.2022.51162 - Ohm J, Skoglund PH, Häbel H, et al. Association of Socioeconomic Status with Risk Factor Target Achievements and Use of Secondary Prevention after Myocardial Infarction. JAMA Network Open. 2021; 4(3):
e211129 –e211129. DOI: 10.1001/jamanetworkopen.2021.1129 - Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018; 137(20): 2166–2178. DOI: 10.1161/CIRCULATIONAHA.117.029652
- Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of Diet, Exercise, and Smoking Modification with Risk of Early Cardiovascular Events after Acute Coronary Syndromes. Circulation. 2010; 121(6): 750–758. DOI: 10.1161/CIRCULATIONAHA.109.891523
- Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the Lifestyle, Risk Factor and Therapeutic Management of Coronary Patients from 24 European Countries. Eur J Prev Cardiol. 2016; 23(6): 636–648. DOI: 10.1177/2047487315569401
- Murray J, Craigs CL, Hill KM, Honey S, House A. A Systematic Review of Patient Reported Factors Associated with Uptake and Completion of Cardiovascular Lifestyle Behaviour Change. BMC Cardiovascular Disorders. 2012; 12(1): 1–12. DOI: 10.1186/1471-2261-12-120
- Kolandaivelu K, Leiden Bb, O’gara Pt, Bhatt Dl. Non-Adherence to Cardiovascular Medications. Eur Heart J. 2014; 35(46): 3267–3276. DOI: 10.1093/eurheartj/ehu364
- Simon ST, Kini V, Levy AE, Ho PM. Medication Adherence in Cardiovascular Medicine. Bmj. 2021; 374. DOI: 10.1136/bmj.n1493
- Chowdhury R, Khan H, Heydon E, et al. Adherence to Cardiovascular Therapy: A Meta-Analysis of Prevalence and Clinical Consequences. Eur Heart J. 2013; 34(38): 2940–2948. DOI: 10.1093/eurheartj/eht295
- Bansilal S, Castellano JM, Garrido E, et al. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. Journal of the American College of Cardiology. 2016; 68(8): 789–801. DOI: 10.1016/j.jacc.2016.06.005
- De Backer G, Jankowski P, Kotseva K, et al. Management of Dyslipidaemia in Patients with Coronary Heart Disease: Results from the ESC-EORP EUROASPIRE V Survey in 27 Countries. Atherosclerosis. 2019; 285: 135–146. DOI: 10.1016/j.atherosclerosis.2019.03.014
- Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021; 28(11): 1279–1289. DOI: 10.1093/eurjpc/zwaa047
- Rosenbaum L. Beyond belief—How People Feel About Taking Medications For Heart Disease. In Vol 372: Mass Medical Soc; 2015: 183–187. DOI: 10.1056/NEJMms1409015
- Lauffenburger, JC, Isaac T, Bhattacharya R, Sequist TD, Gopalakrishnan C, Choudhry NK. Prevalence and Impact of Having Multiple Barriers to Medication Adherence in Nonadherent Patients with Poorly Controlled Cardiometabolic Disease. Am J Cardiol. 2020; 125(3): 376–382. DOI: 10.1016/j.amjcard.2019.10.043
- Magnani JW, Mujahid MS, Aronow HD, et al. Health Literacy and Cardiovascular Disease: Fundamental Relevance to Primary and Secondary Prevention: A Scientific Statement from the American Heart Association. Circulation. 2018; 138(2): e48–e74. DOI: 10.1161/CIR.0000000000000579
- Navar AM, Wang TY, Mi X, et al. Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. JAMA Cardiol. 2018; 3(12): 1192–1199. DOI: 10.1001/jamacardio.2018.3680
- Balady GJ, Ades PA, Bittner VA, et al. Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Prevention Programs at Clinical Centers and Beyond: A Presidential Advisory from the American Heart Association. Circulation. 2011; 124(25): 2951–2960. DOI: 10.1161/CIR.0b013e31823b21e2
- Choudhry NK, Avorn J, Glynn RJ, et al. Full Coverage for Preventive Medications after Myocardial Infarction. N Engl J Med. 2011; 365(22): 2088–2097. DOI: 10.1056/NEJMsa1107913
- Liprandi ÁS, Liprandi MIS, Zaidel EJ, et al. Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus Document of the Inter-American Society of Cardiology and the Word Heart Federation. Glob Heart. 2021; 16(1): 55. DOI: 10.5334/gh.1069
- Chow CK, Nguyen TN, Marschner S, et al. Availability and Affordability of Medicines and Cardiovascular Outcomes in 21 High-Income, Middle-Income and Low-Income Countries. BMJ Global Health. 2020; 5(11):
e002640 . DOI: 10.1136/bmjgh-2020-002640 - Attaei MW, Khatib R, McKee M, et al. Availability and Affordability of Blood Pressure-Lowering Medicines and the Effect On Blood Pressure Control in High-Income, Middle-Income, and Low-Income Countries: an Analysis of the PURE Study Data. The Lancet Public Health. 2017; 2(9): e411–e419. DOI: 10.1016/S2468-2667(17)30141-X
- Khatib R, McKee M, Shannon H, et al. Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-Income, Middle-Income, and Low-Income Countries: An Analysis of the PURE Study Data. The Lancet. 2016; 387(10013): 61–69. DOI: 10.1016/S0140-6736(15)00469-9
- Grace SL, Kotseva K, Whooley MA. Cardiac Rehabilitation: Under-Utilized Globally. Current Cardiology Reports. 2021; 23: 1–8. DOI: 10.1007/s11886-021-01543-x
- Taylor R, Fredericks S, Jones I, et al. Global Perspectives on Heart Disease Rehabilitation and Secondary Prevention: A Scientific Statement from the Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), and International Council of Cardiovascular Prevention and Rehabilitation (ICCPR). European Heart Journal; 2023. DOI: 10.1093/eurheartj/ehad225
- Moledina A, Tang KL. Socioeconomic Status, Mortality, and Access to Cardiac Services after Acute Myocardial Infarction in Canada: A Systematic Review and Meta-Analysis. CJC Open. 2021; 3(7): 950–964. DOI: 10.1016/j.cjco.2021.02.006
- Mamataz T, Uddin J, Alam SI, et al. Effects Of Cardiac Rehabilitation in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Progress in Cardiovascular Diseases. 2022; 70: 119–174. DOI: 10.1016/j.pcad.2021.07.004
- González-Salvado V, Peña-Gil C, Lado-Baleato Ó, et al. Offering, Participation and Adherence to Cardiac Rehabilitation Programmes in the Elderly: A European comparison based on the EU-CaRE multicentre observational study. Eur J Prev Cardiol. 2021; 28(5): 558–568. DOI: 10.1093/eurjpc/zwaa104
- Chow CK, Brieger D, Ryan M, Kangaharan N, Hyun KK, Briffa T. Secondary Prevention Therapies in Acute Coronary Syndrome and Relation to Outcomes: Observational Study. Heart Asia. 2019; 11(1). DOI: 10.1136/heartasia-2018-011122
- Khatib R, McKee M, Shannon H, et al. Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-Income, Middle-Income, and Low-Income Countries: An Analysis of the PURE Study Data. Lancet. 2016; 387(10013): 61–69. DOI: 10.1016/S0140-6736(15)00469-9
- Underberg J, Toth PP, Rodriguez F. LDL-C Target Attainment in Secondary Prevention of ASCVD in the United States: Barriers, Consequences of Nonachievement, and Strategies to Reach Goals. Postgraduate Medicine. 2022; 134(8): 752–762. DOI: 10.1080/00325481.2022.2117498
- Cabana MD, Rand CS, Powe NR, et al. Why Don’t Physicians Follow Clinical Practice Guidelines? A Framework for Improvement. Jama. 1999; 282(15): 1458–1465. DOI: 10.1001/jama.282.15.1458
- Lebeau JP, Cadwallader JS, Vaillant-Roussel H, et al. General Practitioners’ Justifications for Therapeutic Inertia in Cardiovascular Prevention: An Empirically Grounded Typology. BMJ Open. 2016; 6(5):
e010639 . DOI: 10.1136/bmjopen-2015-010639 - Lewinski AA, Jazowski SA, Goldstein KM, Whitney C, Bosworth HB, Zullig LL. Intensifying Approaches to Address Clinical Inertia among Cardiovascular Disease Risk Factors: A Narrative Review. Patient Educ Couns. 2022; 105(12): 3381–3388. DOI: 10.1016/j.pec.2022.08.005
- van Dijk WB, Schuit E, van der Graaf R, et al. Applicability of European Society of Cardiology Guidelines According to Gross National Income. European Heart Journal; 2023. DOI: 10.1093/eurheartj/ehac606
- Oliveira GMMd, Mendes M, Malachias MVB, et al. 2017 Guidelines for Arterial Hypertension Management in Primary Health Care in Portuguese Language Countries. Arquivos brasileiros de cardiologia. 2017; 109: 389–396. DOI: 10.5935/abc.20170165
- Oliveira GMMd, Mendes M, Dutra OP, et al. 2019: Recommendations for Reducing Tobacco Consumption in Portuguese-Speaking Countries-Positioning of the Federation of Portuguese Language Cardiology Societies. Arquivos Brasileiros de Cardiologia. 2019; 112: 477–486. DOI: 10.5935/abc.20190071
- Primary health care. World Health Organization.
https://www.who.int/news-room/fact-sheets/detail/primary-health-care . Published 2021. Accessed. - Starfield B, Shi L, Macinko J. Contribution of Primary Care to Health Systems and Health. The Milbank Quarterly. 2005; 83(3): 457–502. DOI: 10.1111/j.1468-0009.2005.00409.x
- Fixing Britain’s health service means fixing its family doctors. The Economist.
https://www.economist.com/leaders/2023/01/12/fixing-britains-health-service-means-fixing-its-family-doctors . Published 2023. Accessed. - AMA warns GP practices face collapse because of funding crisis. Australian Medical Association.
https://www.ama.com.au/ama-rounds/3-february-2023/articles/ama-warns-gp-practices-face-collapse-because-funding-crisis . Published 2023. Accessed. - Chow CK, Lock K, Teo K, Subramanian S, McKee M, Yusuf S. Environmental and Societal Influences Acting on Cardiovascular Risk Factors and Disease at a Population Level: A Review. International J Epidemiol. 2009; 38(6): 1580–1594. DOI: 10.1093/ije/dyn258
- Mendis S. Global Progress in Prevention of Cardiovascular Disease. Cardiovasc Diagn Ther. 2017; 7(Suppl 1): S32–s38. DOI: 10.21037/cdt.2017.03.06
- Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19—A Dangerous Convergence for Black Americans. N Eng J Med. 2020; 383(12):
e77 . DOI: 10.1056/NEJMp2023616 - Homan P. Structural Sexism and Health in the United States: A New Perspective on Health Inequality and the Gender System. American Sociological Review. 2019; 84(3): 486–516. DOI: 10.1177/0003122419848723
- Mufarreh A, Shah AJ, Vaccarino V, Kulshreshtha A. Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients with Atherosclerotic Cardiovascular Disease, 2006–2016. JAMA Network Open. 2023; 6(1):
e2251156 –e2251156. DOI: 10.1001/jamanetworkopen.2022.51156 - Caceres BA, Brody AA, Halkitis PN, Dorsen C, Yu G, Chyun DA. Sexual Orientation Differences in Modifiable Risk Factors for Cardiovascular Disease and Cardiovascular Disease Diagnoses in Men. LGBT Health. 2018; 5(5): 284–294. DOI: 10.1089/lgbt.2017.0220
- Caceres BA, Brody AA, Halkitis PN, Dorsen C, Yu G, Chyun DA. Cardiovascular Disease Risk in Sexual Minority Women (18–59 Years Old): Findings from the National Health and Nutrition Examination Survey (2001–2012). Women’s Health Issues. 2018; 28(4): 333–341. DOI: 10.1016/j.whi.2018.03.004
- Caceres BA, Brody A, Luscombe RE, et al. A Systematic Review of Cardiovascular Disease in Sexual Minorities. Am J Public Health. 2017; 107(4): e13–e21. DOI: 10.2105/AJPH.2016.303630
- Caceres BA, Sharma Y, Ravindranath R, et al. Differences in Ideal Cardiovascular Health Between Sexual Minority and Heterosexual Adults. JAMA Cardiology. 2023; 8(4): 335–346. DOI: 10.1001/jamacardio.2022.5660
- Javed Z, Haisum Maqsood M, Yahya T, et al. Race, Racism, and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic Disparities in Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes. 2022; 15(1):
e007917 . DOI: 10.1161/CIRCOUTCOMES.121.007917 - Churchwell K, Elkind MS, Benjamin RM, et al. Call to Action: Structural Racism as A Fundamental Driver of Health Disparities: A Presidential Advisory from the American Heart Association. Circulation. 2020; 142(24): e454–e468. DOI: 10.1161/CIR.0000000000000936
- Addo J, Bhalla A, Crichton S, Rudd AG, McKevitt C, Wolfe CD. Provision of Acute Stroke Care and Associated Factors in a Multiethnic Population: Prospective Study with the South London Stroke Register. Bmj. 2011; 342. DOI: 10.1136/bmj.d744
- Asthana S, Moon G, Gibson A, Bailey T, Hewson P, Dibben C. Inequity in Cardiovascular Care in the English National Health Service (NHS): A Scoping Review of the Literature. Health & Social Care in the Community. 2018; 26(3): 259–272. DOI: 10.1111/hsc.12384
- Mindell J, Klodawski E, Fitzpatrick J. Using Routine Data to Measure Ethnic Differentials in Access to Coronary Revascularization. J Public Health. 2008; 30(1): 45–53. DOI: 10.1093/pubmed/fdm077
- The Health of People from Ethnic Minority Groups in England. The King’s Fund.
https://www.kingsfund.org.uk/publications/health-people-ethnic-minority-groups-england#data . Published 2023. Accessed 5 Jun 2023. - Xia S, Du X, Guo L, et al. Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. Circulation. 2020; 141(7): 530–539. DOI: 10.1161/CIRCULATIONAHA.119.043731
- Hyun K, Negrone A, Redfern J, et al. Gender Difference in Secondary Prevention of Cardiovascular Disease and Outcomes Following the Survival of Acute Coronary Syndrome. Heart, Lung and Circulation. 2021; 30(1): 121–127. DOI: 10.1016/j.hlc.2020.06.026
- Lee CMY, Mnatzaganian G, Woodward M, et al. Sex Disparities in the Management of Coronary Heart Disease in General Practices in Australia. Heart. 2019; 105(24): 1898–1904. DOI: 10.1136/heartjnl-2019-315134
- Oosenbrug E, Marinho RP, Zhang J, et al. Sex Differences in Cardiac Rehabilitation Adherence: A Meta-Analysis. Can J Cardiol. 2016; 32(11): 1316–1324. DOI: 10.1016/j.cjca.2016.01.036
- Sanderson BK, Bittner V. Women in Cardiac Rehabilitation: Outcomes and Identifying Risk for Dropout. Am Heart J. 2005; 150(5): 1052–1058. DOI: 10.1016/j.ahj.2004.12.027
- Kuehn BM. Women May Benefit from Cardiac Rehabilitation Programs Tailored to Their Specific Needs. Circulation. 2017; 135(6): 612–613. DOI: 10.1161/CIRCULATIONAHA.116.027064
- Beckie TM, Beckstead JW. Predicting Cardiac Rehabilitation Attendance in A Gender-Tailored Randomized Clinical Trial. J Cardiopulm Rehabil Prev. 2010; 30(3): 147–156. DOI: 10.1097/HCR.0b013e3181d0c2ce
- Kindig DA, Panzer AM, Nielsen-Bohlman L. Health Literacy: A Prescription to End Confusion; 2004. DOI: 10.17226/10883
- Mayberry LS, Schildcrout JS, Wallston KA, et al. Health Literacy and 1-Year Mortality: Mechanisms of Association in Adults Hospitalized for Cardiovascular Disease. Paper Presented at: Mayo Clinic Proceedings; 2018. DOI: 10.1016/j.mayocp.2018.07.024
- Diederichs C, Jordan S, Domanska O, Neuhauser H. Health Literacy in Men and Women with Cardiovascular Diseases and Its Association with the Use of Health Care Services-Results from the Population-Based GEDA2014/2015-EHIS Survey in Germany. PLoS One. 2018; 13(12):
e0208303 . DOI: 10.1371/journal.pone.0208303 - Nutbeam D. The Evolving Concept of Health Literacy. Social Science & Medicine. 2008; 67(12): 2072–2078. DOI: 10.1016/j.socscimed.2008.09.050
- Nutbeam D. Health Literacy as a Public Health Goal: A Challenge for Contemporary Health Education and Communication Strategies into the 21st Century. Health Promotion International. 2000; 15(3): 259–267. DOI: 10.1093/heapro/15.3.259
- Health Literacy Universal Precautions Toolkit, 2nd Edition. Agency for Healthcare Research and Quality.
https://www.ahrq.gov/health-literacy/improve/precautions/toolkit.html . Published 2020. Accessed. - Elwyn G, Cochran N, Pignone M. Shared Decision Making—The Importance of Diagnosing Preferences. JAMA Internal Medicine. 2017; 177(9): 1239–1240. DOI: 10.1001/jamainternmed.2017.1923
- Stacey D, Légaré F, Col NF, et al. Decision Aids for People Facing Health Treatment or Screening Decisions. Cochrane Database Syst Rev. 2014(1):
Cd001431 . DOI: 10.1002/14651858.CD001431.pub4 - Shay LA, Lafata JE. Where Is the Evidence? A Systematic Review of Shared Decision Making and Patient Outcomes. Med Decis Making. 2015; 35(1): 114–131. DOI: 10.1177/0272989X14551638
- The Patient Education Materials Assessment Tool (PEMAT) and User’s Guide. Agency for Healthcare Research and Quality.
https://www.ahrq.gov/health-literacy/patient-education/pemat.html . Published 2020. Accessed. - Elwyn G, O’Connor AM, Bennett C, et al. Assessing the Quality of Decision Support Technologies Using the International Patient Decision Aid Standards instrument (IPDASi). PloS one. 2009; 4(3):
e4705 . DOI: 10.1371/journal.pone.0004705 - Beauchamp A, Talevski J, Niebauer J, et al. Health Literacy Interventions for Secondary Prevention of Coronary Artery Disease: A Scoping Review. Open Heart. 2022; 9(1). DOI: 10.1136/openhrt-2021-001895
- Jonkman NH, Schuurmans MJ, Jaarsma T, Shortridge-Baggett LM, Hoes AW, Trappenburg JC. Self-Management Interventions: Proposal and Validation of a New Operational Definition. Journal of Clinical Epidemiology. 2016; 80: 34–42. DOI: 10.1016/j.jclinepi.2016.08.001
- Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological Health, Well-Being, and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart Association. Circulation. 2021; 143(10): e763–e783. DOI: 10.1161/CIR.0000000000000947
- Krist AH, Davidson KW, Mangione CM, et al. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement. Jama. 2020; 324(20): 2069–2075. DOI: 10.1001/jama.2020.21749
- Sisti LG, Dajko M, Campanella P, Shkurti E, Ricciardi W, De Waure C. The Effect of Multifactorial Lifestyle Interventions on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Trials Conducted in the General Population and High Risk Groups. Preventive Medicine. 2018; 109: 82–97. DOI: 10.1136/bmjopen-2016-015332
- Kvarnström K, Airaksinen M, Liira H. Barriers and Facilitators to Medication Adherence: A Qualitative Study with General Practitioners. BMJ Open. 2018; 8(1):
e015332 . DOI: 10.1136/bmjopen-2016-015332 - Adusumalli S, Aragam G, Patel M. A Nudge towards Cardiovascular Health: Applications of Behavioral Economics for Primary and Secondary Cardiovascular Prevention. Current Treatment Options in Cardiovascular Medicine. 2020; 22: 1–17. DOI: 10.1007/s11936-020-00824-y
- Chokshi NP, Adusumalli S, Small DS, et al. Loss-Framed Financial Incentives and Personalized Goal-Setting to Increase Physical Activity among Ischemic Heart Disease Patients Using Wearable Devices: The ACTIVE REWARD Randomized Trial. Journal of the American Heart Association. 2018; 7(12):
e009173 . DOI: 10.1161/JAHA.118.009173 - Adusumalli S, Kanter GP, Small DS, et al. Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing: A Cluster Randomized Clinical Trial. JAMA cardiology. 2023; 8(1): 23–30. DOI: 10.1001/jamacardio.2022.4373
- T O’Hagan E, McIntyre D, Nguyen T, Chow CK. Hypertension Therapy Using Fixed-Dose Polypills That Contain at Least Three Medications. Heart; 2023. DOI: 10.1136/heartjnl-2022-321496
- Medication use for secondary prevention after coronary heart disease hospitalisations. Australian Institute of Health and Welfare; 2022.
- Peiris D, Usherwood T, Panaretto K, et al. The Treatment of cardiovascular Risk in Primary care using Electronic Decision supOrt (TORPEDO) Study-Intervention Development and Protocol For A Cluster Randomised, Controlled Trial of an Electronic Decision Support and Quality Improvement Intervention in Australian Primary Healthcare. BMJ Open. 2012; 2(6). DOI: 10.1136/bmjopen-2012-002177
- Peiris DP, Joshi R, Webster RJ, et al. An Electronic Clinical Decision Support Tool to Assist Primary Care Providers in Cardiovascular Disease Risk Management: Development and Mixed Methods Evaluation. J Med Internet Res. 2009; 11(4):
e51 . DOI: 10.2196/jmir.1258 - Webster R, Usherwood T, Joshi R, et al. An Electronic Decision Support-Based Complex Intervention to Improve Management of Cardiovascular Risk in Primary Health Care: A Cluster Randomised Trial (INTEGRATE). Med J Aust. 2021; 214(9): 420–427. DOI: 10.5694/mja2.51030
- Buckley BS, Byrne MC, Smith SM. Service organisation for the secondary prevention of ischaemic heart disease in primary care. Cochrane Database of Systematic Reviews. 2010; 3. DOI: 10.1002/14651858.CD006772.pub2
- Murphy E, Vellinga A, Byrne M, et al. Primary Care Organisational Interventions for Secondary Prevention of Ischaemic Heart Disease: A Systematic Review and Meta-Analysis. British Journal of General Practice. 2015; 65(636): e460–e468. DOI: 10.3399/bjgp15X685681
- Clark AM, Hartling L, Vandermeer B, Lissel SL, McAlister FA. Secondary Prevention Programmes for Coronary Heart Disease: A Meta-Regression Showing the Merits of Shorter, Generalist, Primary Care-Based Interventions. European Journal of Cardiovascular Prevention & Rehabilitation. 2007; 14(4): 538–546. DOI: 10.1097/HJR.0b013e328013f11a
- Ades PA, Keteyian SJ, Wright JS, et al. Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative. Mayo Clin Proc. 2017; 92(2): 234–242. DOI: 10.1016/j.mayocp.2016.10.014
- Adusumalli S, Jolly E, Chokshi NP, et al. Referral Rates for Cardiac Rehabilitation Among Eligible Inpatients After Implementation of a Default Opt-Out Decision Pathway in the Electronic Medical Record. JAMA Netw Open. 2021; 4(1):
e2033472 . DOI: 10.1001/jamanetworkopen.2020.33472 - Catapano AL, De Caterina R, Jukema JW, et al. Addressing Current Challenges in Optimization of Lipid Management Following an ACS Event: Outcomes of the ACS EuroPath III Initiative. Clinical Cardiology. 2023; 46(4): 407–415. DOI: 10.1002/clc.23988
- Michos ED, Udell JA. Am I Getting the Influenza Shot Too? Influenza Vaccination as Post-Myocardial Infarction Care for the Prevention of Cardiovascular Events and Death. Circulation. 2021; 144(18): 1485–1488. DOI: 10.1161/CIRCULATIONAHA.121.057534
- Jafri SH, Imran TF, Medbury E, et al. Cardiovascular Outcomes of Patients Referred to Home Based Cardiac Rehabilitation. Heart Lung. 2022; 52: 1–7. DOI: 10.1016/j.hrtlng.2021.11.005
- Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac Rehabilitation for Patients with Heart Failure: JACC Expert Panel. J Am Coll Cardiol. 2021; 77(11): 1454–1469. DOI: 10.1016/j.jacc.2021.01.030
- Pack QR, Johnson LL, Barr LM, et al. Improving Cardiac Rehabilitation Attendance and Completion through Quality Improvement Activities and a Motivational Program. J Cardiopulm Rehabil Prev. 2013; 33(3): 153–159. DOI: 10.1097/HCR.0b013e31828db386
- Seaman KL, Bulsara MK, Sanfilippo FM, et al. Exploring the Association between Stroke and Acute Myocardial Infarction and Statins Adherence Following a Medicines Co-Payment Increase. Res Social Adm Pharm. 2021; 17(10): 1780–1785. DOI: 10.1016/j.sapharm.2021.01.011
- Wawruch M, Wimmer G,
Jr. , Murin J, et al. Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease. Drugs Aging. 2019; 36(9): 863–873. DOI: 10.1007/s40266-019-00689-2 - Cheen MHH, Tan YZ, Oh LF, Wee HL, Thumboo J. Prevalence of and Factors Associated with Primary Medication Non-Adherence in Chronic Disease: A Systematic Review and Meta-Analysis. Int J Clin Pract. 2019; 73(6):
e13350 . DOI: 10.1111/ijcp.13350 - Hernández-Izquierdo C, González López-Valcárcel B, Morris S, Melnychuk M, Abásolo Alessón I. The Effect of a Change in Co-Payment on Prescription Drug Demand in a National Health System: The Case of 15 Drug Families by Price Elasticity of Demand. PLoS One. 2019; 14(3):
e0213403 . DOI: 10.1371/journal.pone.0213403 - Dillon P, Smith SM, Gallagher P, Cousins G. Impact of Financial Burden, Resulting from Prescription Co-Payments, on Antihypertensive Medication Adherence in an Older Publically Insured Population. BMC Public Health. 2018; 18(1):
1282 . DOI: 10.1186/s12889-018-6209-8 - Ofori-Asenso R, Ilomäki J, Tacey M, et al. Predictors of First-Year Nonadherence and Discontinuation of Statins among Older Adults: A Retrospective Cohort Study. Br J Clin Pharmacol. 2019; 85(1): 227–235. DOI: 10.1111/bcp.13797
- van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors Associated with Antihypertensive Medication Non-Adherence: A Systematic Review. J Hum Hypertens. 2017; 31(11): 687–694. DOI: 10.1038/jhh.2017.48
- McRae I, van Gool K, Hall J, Yen L. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins. Appl Health Econ Health Policy. 2017; 15(5): 625–634. DOI: 10.1007/s40258-017-0336-8
- Campbell DJT, Mitchell C, Hemmelgarn BR, et al. Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial. Circulation. 2023; 147(20): 1505–1514. DOI: 10.1161/CIRCULATIONAHA.123.064188
- Fanaroff AC, Peterson ED, Kaltenbach LA, et al. Copayment Reduction Voucher Utilization and Associations with Medication Persistence and Clinical Outcomes: Findings from the ARTEMIS Trial. Circulation: Cardiovascular Quality and Outcomes. 2020; 13(5):
e006182 . DOI: 10.1161/CIRCOUTCOMES.119.006182 - Kuwabara M, Mori M, Komoto S. Japanese National Plan for Promotion of Measures against Cerebrovascular and Cardiovascular Disease. Circulation. 2021; 143(20): 1929–1931. DOI: 10.1161/CIRCULATIONAHA.120.052737
- Lane C, Glassman A, Smitham E. Using Health Taxes to Support Revenue: An Action Agenda for the IMF and World Bank; 2021.
- World Health Organization. Fiscal policies for diet and the prevention of noncommunicable diseases; 2016.
- Andreyeva T, Marple K, Moore TE, Powell LM. Evaluation of Economic and Health Outcomes Associated With Food Taxes and Subsidies: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(6):
e2214371 . DOI: 10.1001/jamanetworkopen.2022.14371 - Afshin A, Peñalvo JL, Del Gobbo L, et al. The Prospective Impact of Food Pricing on Improving Dietary Consumption: A Systematic Review and Meta-Analysis. PLoS One. 2017; 12(3):
e0172277 . DOI: 10.1371/journal.pone.0172277 - Alagiyawanna A, Townsend N, Mytton O, Scarborough P, Roberts N, Rayner M. Studying the Consumption and Health Outcomes of Fiscal Interventions (Taxes and Subsidies) on Food and Beverages in Countries of Different Income Classifications; A Systematic Review. BMC Public Health. 2015; 15:
887 . DOI: 10.1186/s12889-015-2201-8 - Andreyeva T, Long MW, Brownell KD. The Impact of Food Prices on Consumption: A Systematic Review of Research on the Price Elasticity of Demand for Food. Am J Public Health. 2010; 100(2): 216–222. DOI: 10.2105/AJPH.2008.151415
- Powell LM, Chriqui JF, Khan T, Wada R, Chaloupka FJ. Assessing the Potential Effectiveness of Food and Beverage Taxes and Subsidies for Improving Public Health: A Systematic Review of Prices, Demand and Body Weight Outcomes. Obes Rev. 2013; 14(2): 110–128. DOI: 10.1111/obr.12002
- Zhang W, Lin S, Hopke PK, et al. Triggering of Cardiovascular Hospital Admissions by Fine Particle Concentrations in New York State: Before, During, and after Implementation of Multiple Environmental Policies and a Recession. Environ Pollut. 2018; 242(Pt B): 1404–1416. DOI: 10.1016/j.envpol.2018.08.030
- Alcaraz A, Bardach AE, Espinola N, et al. Health and Economic Burden of Disease of Sugar-Sweetened Beverage Consumption in Four Latin American and Caribbean Countries: A Modelling Study. BMJ Open. 2023; 13(2):
e062809 . DOI: 10.1136/bmjopen-2022-062809 - Basto-Abreu A, Barrientos-Gutiérrez T, Vidaña-Pérez D, et al. Cost-Effectiveness of the Sugar-Sweetened Beverage Excise Tax in Mexico. Health Aff (Millwood). 2019; 38(11): 1824–1831. DOI: 10.1377/hlthaff.2018.05469
- Malik VS, Hu FB. The Role of Sugar-Sweetened Beverages in the Global Epidemics of Obesity and Chronic Diseases. Nat Rev Endocrinol. 2022; 18(4): 205–218. DOI: 10.1038/s41574-021-00627-6
- Brørs G, Pettersen TR, Hansen TB, et al. Modes of e-Health Delivery in Secondary Prevention Programmes for Patients with Coronary Artery Disease: A Systematic Review. BMC Health Services Research. 2019; 19: 1–24. DOI: 10.1186/s12913-019-4106-1
- Jensen MT, Treskes RW, Caiani EG, et al. ESC Working Group on E-Cardiology Position Paper: Use of Commercially Available Wearable Technology for Heart Rate and Activity Tracking in Primary and Secondary Cardiovascular Prevention—In Collaboration with the European Heart Rhythm Association, European Association of Preventive Cardiology, Association of Cardiovascular Nursing and Allied Professionals, Patient Forum, and the Digital Health Committee. European Heart Journal-Digital Health. 2021; 2(1): 49–59. DOI: 10.1093/ehjdh/ztab011
- Su JJ, Liu JYW, Cheung DSK, et al. Long-term Effects of eHealth Secondary Prevention on Cardiovascular Health: A Systematic Review and Meta-Analysis. European Journal of Cardiovascular Nursing. 2023;
zvac116 . - WHO. WHO Classification of Digital Health Interventions v1.0. World Health Organization.
https://apps.who.int/iris/bitstream/handle/10665/260480/WHO-RHR-18.06-eng.pdf . Published 2018. Accessed 2023. - Shariful Islam SM, Farmer AJ, Bobrow K, et al. Mobile Phone Text-Messaging Interventions Aimed to Prevent Cardiovascular Diseases (Text2PreventCVD): Systematic Review and Individual Patient Data Meta-Analysis. Open Heart. 2019; 6(2):
e001017 . DOI: 10.1136/openhrt-2019-001017 - Cruz-Cobo C, Bernal-Jiménez M, Vázquez-García R, Santi-Cano MJ. Effectiveness of mHealth Interventions in the Control of Lifestyle and Cardiovascular Risk Factors in Patients After a Coronary Event: Systematic Review and Meta-analysis. JMIR Mhealth Uhealth. 2022; 10(12):
e39593 . DOI: 10.2196/39593 - Thakkar J, Kurup R, Laba TL, et al. Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease: A Meta-analysis. JAMA Intern Med. 2016; 176(3): 340–349. DOI: 10.1001/jamainternmed.2015.7667
- Chow CK, Redfern J, Hillis GS, et al. Effect of Lifestyle-Focused Text Messaging on Risk Factor Modification in Patients with Coronary Heart Disease: A Randomized Clinical Trial. Jama. 2015; 314(12): 1255–1263. DOI: 10.1001/jama.2015.10945
- Chow CK, Thiagalingam A, Santo K, et al. TEXT Messages to Improve MEDication Adherence and Secondary Prevention (TEXTMEDS) after Acute Coronary Syndrome: A Randomised Clinical Trial Protocol. BMJ open. 2018; 8(1):
e019463 . DOI: 10.1136/bmjopen-2017-019463 - Xiong S, Lu H, Peoples N, et al. Digital Health Interventions for Non-Communicable Disease Management in Primary Health Care in Low- and Middle-Income Countries. NPJ Digital Medicine. 2023; 6(1): 12. DOI: 10.1038/s41746-023-00764-4
- Tong HL, Quiroz JC, Kocaballi AB, et al. Personalized Mobile Technologies for Lifestyle Behavior Change: A Systematic Review, Meta-Analysis, and Meta-Regression. Preventive Medicine. 2021; 148:
106532 . DOI: 10.1016/j.ypmed.2021.106532 - Laranjo L, Ding D, Heleno B, et al. Do Smartphone Applications and Activity Trackers Increase Physical Activity in Adults? Systematic Review, Meta-Analysis and Metaregression. British Journal of Sports Medicine. 2021; 55(8): 422–432. DOI: 10.1136/bjsports-2020-102892
- Frederix I, Caiani EG, Dendale P, et al. ESC e-Cardiology Working Group Position Paper: Overcoming Challenges in Digital Health Implementation in Cardiovascular Medicine. European Journal of Preventive Cardiology. 2019; 26(11): 1166–1177. DOI: 10.1177/2047487319832394
- Devi R, Singh SJ, Powell J, Fulton EA, Igbinedion E, Rees K. Internet-Based Interventions for the Secondary Prevention of Coronary Heart Disease. Cochrane Database of Systematic Reviews; 2015(12). DOI: 10.1002/14651858.CD009386.pub2
- Sarraju A, Bruemmer D, Van Iterson E, Cho L, Rodriguez F, Laffin L. Appropriateness of cardiovascular Disease Prevention Recommendations Obtained from a Popular Online Chat-Based Artificial Intelligence Model. JAMA. 2023; 329(10): 842–844. DOI: 10.1001/jama.2023.1044
- O’Hagan E, McIntyre D, Laranjo L. Potential for a Chat-Based Artificial Intelligence Model to Facilitate Educational Messaging on Hypertension. Hypertension; 2023. DOI: 10.1161/HYPERTENSIONAHA.123.21395
- Laranjo L, Shaw T, Trivedi R, et al. Coordinating Health Care with Artificial Intelligence–Supported Technology for Patients with Atrial Fibrillation: Protocol for a Randomized Controlled Trial. JMIR Research Protocols; 2022; 11(4):
e34470 . DOI: 10.2196/34470 - Bates DW, Kuperman GJ, Wang S, et al. Ten Commandments for Effective Clinical Decision Support: Making the Practice of Evidence-Based Medicine a Reality. Journal of the American Medical Informatics Association. 2003; 10(6): 523–530. DOI: 10.1197/jamia.M1370
- Kawamato K, Houlihan C, Balas E, Lobach D. Improving Clinical Practice using Clinical Decision Support Systems: A Systematic Review of Trials to Identify Features Critical to Success. British Medical Journal. 2005; 330: 1–8. DOI: 10.1136/bmj.38398.500764.8F
- Njie GJ, Proia KK, Thota AB, et al. Clinical Decision Support Systems and Prevention: A Community Guide Cardiovascular Disease Systematic Review. American Journal of Preventive Medicine. 2015; 49(5): 784–795. DOI: 10.1016/j.amepre.2015.04.006
- Holbrook A, Pullenayegum E, Thabane L, et al. Shared Electronic Vascular Risk Decision Support in Primary Care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) Randomized Trial. Archives of Internal Medicine. 2011; 171(19): 1736–1744. DOI: 10.1001/archinternmed.2011.471
- Kwan JL, Lo L, Ferguson J, et al. Computerised Clinical Decision Support Systems and Absolute Improvements in Care: Meta-Analysis of Controlled Clinical Trials. Bmj. 2020; 370. DOI: 10.1136/bmj.m3216
- Cho I, Bates DW. Behavioral Economics Interventions in Clinical Decision Support Systems. Yearbook of Medical Informatics. 2018; 27(01): 114–121. DOI: 10.1055/s-0038-1641221
- Peiris D, Usherwood T, Panaretto K, et al. Effect of a Computer-Guided, Quality Improvement Program for Cardiovascular Disease Risk Management in Primary Health Care: The Treatment of Cardiovascular Risk Using Electronic Decision Support Cluster-Randomized Trial. Circulation: Cardiovascular Quality and Outcomes. 2015; 8(1): 87–95. DOI: 10.1161/CIRCOUTCOMES.114.001235
- Yan LL, Gong E, Gu W, et al. Effectiveness of a Primary Care-Based Integrated Mobile Health Intervention for Stroke Management in Rural China (SINEMA): A Cluster-Randomized Controlled Trial. Plos Medicine. 2021; 18(4):
e1003582 . DOI: 10.1371/journal.pmed.1003582 - Tian M, Ajay VS, Dunzhu D, et al. A Cluster-Randomized, Controlled Trial of a Simplified Multifaceted Management Program for Individuals at High Cardiovascular Risk (Simcard Trial) in Rural Tibet, China, and Haryana, India. Circulation. 2015; 132(9): 815–824. DOI: 10.1161/CIRCULATIONAHA.115.015373
- Virani SS, Ramsey DJ, Westerman D, et al. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients with Atherosclerotic Cardiovascular Disease. Circulation. 2023; 147(18): 1411–1413. DOI: 10.1161/CIRCULATIONAHA.123.064226
- Ramachandran HJ, Jiang Y, Tam WWS, Yeo TJ, Wang W. Effectiveness of Home-Based Cardiac Telerehabilitation as an Alternative to Phase 2 Cardiac Rehabilitation of Coronary Heart Disease: A Systematic Review and Meta-Analysis. European Journal of Preventive Cardiology. 2022; 29(7): 1017–1043. DOI: 10.1093/eurjpc/zwab106
- Jin K, Khonsari S, Gallagher R, et al. Telehealth Interventions for the Secondary Prevention of Coronary Heart Disease: A Systematic Review and Meta-Analysis. European Journal of Cardiovascular Nursing. 2019; 18(4): 260–271. DOI: 10.1177/1474515119826510
- Lee KC, Breznen B, Ukhova A, Koehler F, Martin SS. Virtual Healthcare Solutions for Cardiac Rehabilitation: A Literature Review. European Heart Journal-Digital Health. 2023; 4(2): 99–111. DOI: 10.1016/j.jaccas.2022.05.027
- Content VG, Abraham HM, Kaihoi BH, Olson TP, Brewer LC. Novel Virtual World-Based Cardiac Rehabilitation Program to Broaden Access to Underserved Populations: A Patient Perspective. Case Reports. 2022; 4(14): 911–914. DOI: 10.1016/j.jaccas.2022.05.027
- Thomas RJ, Beatty AL, Beckie TM, et al. Home-Based Cardiac Rehabilitation: A Scientific Statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019; 140(1): e69–e89. DOI: 10.1161/CIR.0000000000000663
- Anderson L, Sharp GA, Norton RJ, et al. Home-Based versus Centre-Based Cardiac Rehabilitation. Cochrane Database of Systematic Reviews. 2017; 6. DOI: 10.1002/14651858.CD007130.pub4
- Imran HM, Baig M, Erqou S, et al. Home-Based Cardiac Rehabilitation Alone and Hybrid with Center-Based Cardiac Rehabilitation in Heart Failure: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2019; 8(16):
e012779 . DOI: 10.1161/JAHA.119.012779 - Subedi N, Rawstorn JC, Gao L, Koorts H, Maddison R. Implementation of Telerehabilitation Interventions for the Self-Management of Cardiovascular Disease: Systematic Review. JMIR mHealth and uHealth. 2020; 8(11):
e17957 . DOI: 10.2196/17957 - Fisk M, Livingstone A, Pit SW. Telehealth in the Context of COVID-19: Changing Perspectives in Australia, the United Kingdom, and the United States. J Med Internet Res. 2020; 22(6):
e19264 . DOI: 10.2196/19264 - de Melo Ghisi GL, Xu Z, Liu X, et al. Impacts of the COVID-19 Pandemic on Cardiac Rehabilitation Delivery around the World. Global Heart. 2021; 16(1). DOI: 10.5334/gh.939
- Turk-Adawi K, Supervia M, Ghisi G, et al. The Impact of ICCPR’s Global Audit of Cardiac Rehabilitation: Where Are We Now and Where Do We Need To Go? eClinicalMedicine. 2023; 61. DOI: 10.1016/j.eclinm.2023.102092
- Brouwers RWM, Brini A, Kuijpers RWFH, Kraal JJ, Kemps HMC. Predictors of Non-Participation in a Cardiac Telerehabilitation Programme: A Prospective Analysis. European Heart Journal-Digital Health. 2022; 3(1): 81–89. DOI: 10.1093/ehjdh/ztab105
- Vanzella LM, Oh P, Pakosh M, Ghisi GLdM. Barriers and Facilitators to Virtual Education in Cardiac Rehabilitation: A Systematic Review of Qualitative Studies. European Journal of Cardiovascular Nursing. 2022; 21(5): 414–429. DOI: 10.1093/eurjcn/zvab114
- Fuller RH, Perel P, Navarro-Ruan T, Nieuwlaat R, Haynes RB, Huffman MD. Improving Medication Adherence in Patients with Cardiovascular Disease: A Systematic Review. Heart. 2018; 104(15): 1238–1243. DOI: 10.1136/heartjnl-2017-312571
- Thom S, Poulter N, Field J, et al. Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients with or at High Risk of CVD: The UMPIRE Randomized Clinical Trial. Jama. 2013; 310(9): 918–929. DOI: 10.1001/jama.2013.277064
- Castellano JM, Sanz G, Peñalvo JL, et al. A Polypill Strategy to Improve Adherence: Results from the FOCUS Project. J Am Coll Cardiol. 2014; 64(20): 2071–2082. DOI: 10.1016/j.jacc.2014.08.021
- Selak V, Elley CR, Bullen C, et al. Effect of Fixed Dose Combination Treatment on Adherence and Risk Factor Control among Patients at High Risk of Cardiovascular Disease: Randomised Controlled Trial in Primary Care. Bmj. 2014; 348. DOI: 10.1136/bmj.g3318
- Selak V, Webster R, Stepien S, et al. Reaching Cardiovascular Prevention Guideline Targets with a Polypill-Based Approach: A Meta-Analysis of Randomised Clinical Trials. Heart. 2019; 105(1): 42–48. DOI: 10.1136/heartjnl-2018-313108
- Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022; 387(11): 967–977. DOI: 10.1056/NEJMoa2208275
- Sosa-Liprandi Á, Liprandi MIS, Alexánderson E, et al. Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology. Global Heart. 2019; 14(1): 3–16. e11. DOI: 10.1016/j.gheart.2018.10.001
- WHO Model List of Essential Medicines – 23rd List (2023) World Health Organization.
https://apps.who.int/iris/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf . Published 2023. Accessed. - Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016; 316(10): 1093–1103. DOI: 10.1001/jama.2016.12195
- Marquina C, Zomer E, Vargas-Torres S, et al. Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. PharmacoEconomics. 2020; 38(10): 1095–1113. DOI: 10.1007/s40273-020-00936-0
- Ferro EG, Liu C-L, Kazi DS. Cost-Effectiveness and Affordability of Novel Cardiovascular Therapies: What Physicians Need to Know. Heart. 2021; 107(15): 1267–1268. DOI: 10.1136/heartjnl-2021-319055
- Wang X, Wen D, Chen Y, Ma L, You C. PCSK9 Inhibitors for Secondary Prevention in Patients with Cardiovascular Diseases: A Bayesian Network Meta-Analysis. Cardiovascular Diabetology. 2022; 21(1):
107 . DOI: 10.1186/s12933-022-01542-4 - Hlatky MA, Kazi DS. PCSK9 Inhibitors: Economics and Policy. J Am Coll Cardiol. 2017; 70(21): 2677–2687. DOI: 10.1016/j.jacc.2017.10.001
- Kazi DS, Moran AE, Coxson PG, et al. Cost-Effectiveness of PCSK9 Inhibitor Therapy in Patients with Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Jama. 2016; 316(7): 743–753. DOI: 10.1001/jama.2016.11004
- Kazi DS, Virani SS. Implications of Cost-Effectiveness Analyses of Lipid-Lowering Therapies: From the Policy-Maker’s Desk to the Patient’s Bedside. Progress in Cardiovascular Diseases. 2019; 62(5): 406–413. DOI: 10.1016/j.pcad.2019.10.006
- Kazi DS, Wei PC, Penko J, et al. Scaling Up Pharmacist-Led Blood Pressure Control Programs in Black Barbershops: Projected Population Health Impact and Value. Circulation. 2021; 143(24): 2406–2408. DOI: 10.1161/CIRCULATIONAHA.120.051782
- Gaziano TA, Pandya A, Sy S, et al. Modeling the Cost Effectiveness and Budgetary Impact of Polypills for Secondary Prevention of Cardiovascular Disease in the United States. American Heart Journal. 2019; 214: 77–87. DOI: 10.1016/j.ahj.2019.04.020
- Lin JK, Moran AE, Bibbins-Domingo K, et al. Cost-Effectiveness of a Fixed-Dose Combination Pill for Secondary Prevention of Cardiovascular Disease in China, India, Mexico, Nigeria, and South Africa: A Modelling Study. Lancet Glob Health. 2019; 7(10): e1346–e1358. DOI: 10.1016/S2214-109X(19)30339-0
- Jahangiri R, Rezapour A, Malekzadeh R, Olyaeemanesh A, Roshandel G, Motevalian SA. Cost-Effectiveness of Fixed-Dose Combination Pill (Polypill) in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Literature Review. PLoS One. 2022; 17(7):
e0271908 . DOI: 10.1371/journal.pone.0271908 - Burn E, Nghiem S, Jan S, et al. Cost-Effectiveness of a Text Message Programme for the Prevention of Recurrent Cardiovascular Events. Heart. 2017; 103(12): 893–894. DOI: 10.1136/heartjnl-2016-310195
- Bhardwaj V, Spaulding EM, Marvel FA, et al. Cost-Effectiveness of a Digital Health Intervention for Acute Myocardial Infarction Recovery. Med Care. 2021; 59(11): 1023–1030. DOI: 10.1097/MLR.0000000000001636
- Johnson HM, Gorre CE, Friedrich-Karnik A, Gulati M. Addressing the Bias in Cardiovascular Care: Missed & Delayed Diagnosis of Cardiovascular Disease in Women. American Journal of Preventive Cardiology. 2021; 8. DOI: 10.1016/j.ajpc.2021.100299
- Jardim TV, Reiger S, Abrahams-Gessel S, et al. Disparities in Management of Cardiovascular Disease in Rural South Africa: Data From the HAALSI Study (Health and Aging in Africa: Longitudinal Studies of International Network for the Demographic Evaluation of Populations and Their Health Communities). Circ Cardiovasc Qual Outcomes. 2017; 10(11). DOI: 10.1161/CIRCOUTCOMES.117.004094
- Achterberg S, Soedamah-Muthu SS, Cramer MJ, Kappelle LJ, van der Graaf Y, Algra A. Prognostic Value of the Rose Questionnaire: A Validation with Future Coronary Events in the SMART Study. Eur J Prev Cardiol. 2012; 19(1): 5–14. DOI: 10.1177/1741826710391117
- Nazzal C, Frenz P, Alonso FT, Lanas F. Effective Universal Health Coverage and Improved 1-Year Survival after Acute Myocardial Infarction: The Chilean Experience. Health Policy Plan. 2016; 31(6): 700–705. DOI: 10.1093/heapol/czv120
- Yan LL, Gong E, Gu W, et al. Effectiveness of a PrimaryCare-Based Integrated Mobile Health Intervention for Stroke Management in Rural China (SINEMA): A Cluster-Randomized Controlled Trial. PLoS Med. 2021; 18(4):
e1003582 . DOI: 10.1371/journal.pmed.1003582 - Imran TF, Wang N, Zombeck S, Balady GJ. Mobile Technology Improves Adherence to Cardiac Rehabilitation: A Propensity Score-Matched Study. J Am Heart Assoc. 2021; 10(15):
e020482 . DOI: 10.1161/JAHA.120.020482 - Varghese MS, Beatty AL, Song Y, et al. Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent Declines in Cardiac Rehabilitation Participation and Access Among US Medicare Beneficiaries. Circ Cardiovasc Qual Outcomes. 2022; 15(12):
e009618 . DOI: 10.1161/CIRCOUTCOMES.122.009618
DOI: https://doi.org/10.5334/gh.1278 | Journal eISSN: 2211-8179
Language: English
Submitted on: Nov 9, 2023
Accepted on: Nov 16, 2023
Published on: Jan 22, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2024 Liliana Laranjo, Fernando Lanas, Marie Chan Sun, Deborah Anne Chen, Lisa Hynes, Tasnim F. Imran, Dhruv S. Kazi, Andre Pascal Kengne, Maki Komiyama, Masanari Kuwabara, Jeremy Lim, Pablo Perel, Daniel José Piñeiro, Carlos I. Ponte-Negretti, Tania Séverin, David R. Thompson, Lale Tokgözoğlu, Lijing L. Yan, Clara K. Chow, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.